John C. Reed Ranks #1 for Hottest Researcher of 1998-1999
LA JOLLA, Calif. , March 31, 2000
For the second year in a row, Burnham Institute scientific director Dr. John C. Reed has been singled out as the most highly cited researcher in the world in an analysis compiled by the Institute for Scientific Information (ISI). ISI's index of "hot" or high impact research papers for 1998-1999 is published in the March/April edition of ScienceWatch
Dr. Christopher King, editor of ScienceWatch, commented on the significance of "hot" research: "The Institute for Scientific Information looks directly at the scientific literature, specifically the number of citations, to gauge the judgements that scientists themselves make regarding the papers they find to be most significant and useful. Clearly by this measure, Dr. Reed's work is highly central to apoptosis research-one of the most active and visible fields in current biomedicine". Apoptosis, or programmed cell death, is an important counterbalance to "normal" tissue growth. Too much cell death has been associated with certain neurological diseases; too little, or blocking the cell death program altogether, has been identified with certain forms of cancer.
Dr. Reed and his laboratory of over 40 researchers conduct investigations of apoptosis/programmed cell death, with a particular emphasis on understanding the role of cell death in cancer. His research has contributed to a new understanding of tumor biology, which addresses the cells' refusing to die as programmed. This new information is being incorporated into the design of new cancer drugs that work by triggering the cell death program. Reed's research has resulted in over 400 publications and 20 U.S. patent filings to date.
John C. Reed, M.D., Ph.D., in addition to serving as scientific director of The Burnham Institute, also leads the Institute's Apoptosis and Cell Death Program and serves as Deputy Director of the Institute's NCI-designated Cancer Center. Dr. Reed's research is funded by grants from the National Institutes of Health, the Department of Defense, the California Tobacco-Related Disease Research Program, and private funding from CapCURE and the Susan G. Komen Breast Cancer Foundation.